Markets:

Overview

News

Currencies

International

Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

8.980 +0.140 (+1.58%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 29, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Arvinas, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >

These Analysts Increase Their Forecasts On Arvinas After Q1 Results ↗

May 13, 2026

Arvinas Inc (NASDAQ:ARVN) reported Q1 losses of 90 cents/share, missed analyst estimates. Rigel Pharmaceuticals (NASDAQ:RIGL) announced global licensing agreement with Arvinas and Pfizer (NYSE:PFE) for...

Via Benzinga

Arvinas Q1 Earnings Call Highlights ↗

May 12, 2026

Arvinas (NASDAQ:ARVN) said its first quarter was marked by the FDA approval of VEPPANU, a new licensing agreement with Rigel Pharmaceuticals and continued progress across a clinical-stage pipeline...

Via MarketBeat

Topics Earnings

Arvinas (NASDAQ:ARVN) Q1 2026 Results: First-Ever PROTAC Approval Offsets Revenue Miss ↗

May 12, 2026

Via Chartmill

Arvinas (ARVN) Q4 2025 Earnings Call Transcript ↗

February 24, 2026

Arvinas (ARVN) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Arvinas Inc (NASDAQ:ARVN) Stock Plummets After Q4 2025 Earnings and Revenue Miss Estimates ↗

February 24, 2026

Via Chartmill

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

What 4 Analyst Ratings Have To Say About Arvinas ↗

September 17, 2025

Via Benzinga

Wall Street Has Mixed Opinions On Future Of Arvinas’ Investigational Drug: Retail’s Got A Cautious Approach ↗

August 07, 2025

Via Stocktwits

ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff ↗

February 12, 2026

Randy Teel has been appointed as President, CEO, as well as a member of the Company’s Board of Directors, effective immediately.

Via Stocktwits

Top movers in Tuesday's session ↗

November 18, 2025

Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 18, 2025

Via Benzinga

Let's uncover which stocks are experiencing notable gaps during today's session. ↗

November 18, 2025

Today's session on Tuesday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.

Via Chartmill

Earnings Scheduled For August 6, 2025 ↗

August 06, 2025

Via Benzinga

What Analysts Are Saying About Arvinas Stock ↗

June 02, 2025

Via Benzinga

Amer Sports Posts Upbeat Q3 Earnings, Joins Diginex, James Hardie Industries And Other Big Stocks Moving Higher On Tuesday ↗

November 18, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Tuesday. ↗

November 18, 2025

As the US market prepares to open on Tuesday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 18, 2025

Via Benzinga

Arvinas Inc (NASDAQ:ARVN) Tops Q3 2025 Earnings Estimates and Provides Pipeline Updates ↗

November 05, 2025

Arvinas (ARVN) beat Q3 2025 earnings estimates, with revenue of $41.9M and a smaller-than-expected loss. The biotech also reported strong pipeline progress and a cash runway into 2028.

Via Chartmill

Forecasting The Future: 7 Analyst Projections For Arvinas ↗

October 15, 2025

Via Benzinga

This GE Vernova Analyst Turns Bearish; Here Are Top 5 Downgrades For Wednesday ↗

October 15, 2025

Via Benzinga

Karooooo Posts Downbeat Earnings, Joins ASP Isotopes And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 15, 2025

Via Benzinga

Arvinas Inc (NASDAQ:ARVN) Reports Q2 2025 Earnings: Revenue Misses but EPS Beats Estimates ↗

August 06, 2025

Arvinas Q2 2025 earnings: Revenue missed estimates at $22.4M, but EPS beat at -$0.84. NDA submitted for vepdegestrant, ARV-102 advances in trials. Shares fell pre-market.

Via Chartmill

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 18, 2025

Via Benzinga

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

June 09, 2025

Via Benzinga

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval ↗

June 06, 2025

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- breast cancer patients

Via Benzinga

SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 02, 2025

Via Benzinga

Where Arvinas Stands With Analysts ↗

May 05, 2025

Via Benzinga

Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday ↗

May 02, 2025

Via Benzinga

Here are the top movers in Thursday's session. ↗

May 01, 2025

Here are the top movers in Thursday's session, showcasing the stocks with significant price changes.

Via Chartmill

Top stock movements in today's session. ↗

May 01, 2025

Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session.

Via Chartmill

< Previous 1 2 3 4 5 6 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.